Please login to the form below

Not currently logged in
Email:
Password:

Brain tumour vaccine is UK’s first ‘Promising Innovative Medicine’

Northwest Biotherapeutics’ DCVax-L gets UK version of ‘breakthrough’ status for use in cancer
UK flag

A vaccine to treat brain tumours was today designated the UK's first 'Promising Innovative Medicine' (PIM) as part of a scheme to accelerate the availability of medicines for serious diseases.

Northwest Biotherapeutics received the designation for DCVax-L, a personalised immunotherapy that targets malignant gliomas, including glioblastomas – the most severe form of the cancer.

PIM status was introduced in the UK in March this year as part of the Early Access to Medicines scheme. It allows companies to have innovative treatments used in an NHS population once the Medicines and Healthcare Products Regulatory Agency (MHRA) has determined the benefits outweigh the risks.

This bypasses the usual route for new drugs for NHS use, which includes approval from the European Commission and then a cost effectiveness review by the National Institute for Health and Care Excellence (NICE) or the Scottish Medicines Consortium (SMC).

UK Life Sciences Minister George Freeman said: "The designation of the PIM is the first, crucial step in developing cutting-edge medicines sooner, giving real hope to patients and their families."

PIM has been likened to the US FDA's successful 'breakthrough' class and is reserved for new medicines to treat serious life-threatening conditions that are likely to offer a major advantage over currently available treatments.

DCVax-L – a therapy manufactured from a patient's dendritic cells pulsed with tumour cell lysate - qualifies due to the serious nature of malignant gliomas, while the drug has also demonstrated its effectiveness in early clinical trials.

Dendritic Cell Immunotherapy - Northwest Biotherapeutics
 

The process of Dendritic Cell immunotherapy (Northwest Biotherapeutics)

The first designation will come as a relief to the UK Government, which was criticised by some areas of the industry for making the scheme funded by companies who produce the medicine rather than through national reimbursement.

At the time the scheme was announced the BioIndustry Association's CEO Steve Bates lauded its intent, but said it ran the risk of being “under-utilised” due to the nature of its funding.

The cost hasn't halted Northwest Biotherapeutics' ambitions, however, and the company is set to benefit from the experience of having a drug used in a real-world NHS setting, potentially accelerating the process to gain a full licence complete with national reimbursement.

As for next steps, the Department of Health confirmed Northwest Biotherapeutics will continue to develop the medicine and, if proven in trials, it will be eligible to apply for step two of the UK Early Access to Medicines Scheme. It will then go through formal medicines licensing.

Article by
Thomas Meek

16th September 2014

From: Research, Sales, Regulatory, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

the_other_side_of_rheumation_arthritis_thumb.jpg
THE OTHER SIDE OF … RHEUMATOID ARTHRITIS
“I harassed my GP enough to get it caught early”...
The big dilemma in international digital pharma marketing
How to get consistent international marketing while meeting local affiliates’ needs....
Why pharma content marketing campaigns should be agile
Agile pharma content marketing is simply about responding to customer needs, rather than your own whims....

Infographics